
    
      To evaluate the efficacy over 1 year against culture-confirmed influenza-illness caused by
      community-acquired subtypes antigenically similar to those contained in the vaccine, in
      adults aged â‰¥ 60 years at enrollment, of 1 dose of an intranasally-administered (IN) liquid
      formulation of influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T;
      Wyeth, Marietta, PA, USA) compared with saline placebo.
    
  